SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending as a "permissionless brandcoin" captivating the crypto space with its continuous development of real-world products, such as KENDU SPICE and energy drinks, available across multiple blockchains. The highly active and bullish community drives its growth, emphasizing a long-term vision and relentless IRL efforts that set it apart from typical hype-driven projects. This unique blend of tangible utility and strong collective conviction makes KENDU a standout topic among enthusiasts.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid key strategic announcements, including a significant expansion with HD Hyundai in South Korea and a role in building next-gen AI infrastructure across EMEA. CEO Alex Karp's prominent presence at Davos, highlighting AI-driven efficiency and impact, fuels a strong bullish narrative among some investors. Conversely, the community remains divided on its lofty valuation, with others anticipating pullbacks and monitoring broader market volatility.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing a sharp stock decline, sparking widespread investor confusion despite recent financial reports indicating better-than-expected performance. The immediate catalyst appears to be market apprehension regarding the debt impact of its substantial acquisition ambitions and a temporary halt in share buybacks. This has divided the community, with many seizing what they call a 'generational' buying opportunity, while others foresee deeper corrections due to perceived growth moderation and sector competition.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals (CRVS) is trending following its announcement of strong Phase 1 clinical trial data for soquelitinib in atopic dermatitis, showcasing high efficacy and a favorable safety profile that excites investors about its blockbuster potential. While the positive results have fueled significant bullish sentiment and speculation around partnerships, a recently announced public offering has simultaneously introduced dilution concerns, leading to mixed community perspectives.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies (AVR) is trending due to a strategic private placement by Medtronic complementing a recent public offering, sparking significant community speculation about potential future upside and acquisition. This excitement is further fueled by the company's recent commencement of its pivotal DurAVR heart valve trial, with many viewing the stock as currently undervalued.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix Corp is trending amidst mixed community reactions to recent developments, including the departure of its COO and announcements of partnerships with smart eyewear companies Jorjin and L'Attitude 52N at CES. While bulls point to independent testing validating high volumetric energy density for its AI-1 battery and long-term potential in AI-driven devices, many investors express frustration over continued delays in securing significant smartphone orders and perceived inconsistencies in management's execution. The conversation highlights a divide between confidence in the company's patented silicon-anode battery technology and skepticism regarding its ability to achieve mass commercialization.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing a notable surge, primarily fueled by promising 5-year clinical data for its personalized cancer vaccine in collaboration with Merck and recent global regulatory submissions for its seasonal flu vaccine. The community is actively discussing the company's improved financial outlook and strategic shift towards its diverse mRNA pipeline beyond prior vaccine products. This reevaluation is amplified by a significant short interest, with many anticipating continued momentum in the broader biotech sector.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing a parabolic rally to new record highs, driven by escalating US-Europe trade tensions over Greenland and broader global geopolitical uncertainties. The community is buzzing about gold's safe-haven appeal and discussing the potential for a continued ascent towards $5,000 an ounce as investors seek refuge in real assets amidst a climate of market instability and currency debasement concerns.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing heightened trading activity as the community awaits the anticipated finalization of the TikTok U.S. deal while simultaneously reacting to news of a bondholder lawsuit citing undisclosed AI infrastructure debt. Investors are sharply divided, debating whether Oracle's extensive cloud and AI investments will propel future growth or if its increasing debt burden makes it a significant risk.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is surging on the back of severe cold weather forecasts, including polar vortex threats, driving expectations for increased natural gas demand and significant storage withdrawals across the U.S. and Europe. The community is actively discussing a potential short squeeze amid rallying natural gas futures, though many are also highlighting the commodity's notorious volatility and the potential for a swift reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc...

Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN

Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the...

SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit

SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN...

VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vistagen Therapeutics, Inc.

VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vistagen Therapeutics, Inc. VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit...

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire...

Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and...

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (Vistagen or the Company) (NASDAQ: VTGN) for...

Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action

Robbins LLP informs investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1...

<ul class="summary-bullets"><li>PALISADE-3 aimed to assess acute anxiety relief during public speaking challenges.</li><li>Participants received a single intranasal dose of fasedienol and were assessed during a simulated public speaking challenge.</li><li>Lucid Capital downgraded Vistagen stock to ‘Neutral’ from ‘Buy’, and slashed its price target from $19 to $1.</li></ul>Vistagen (VTGN) shares tanked 82% on Wednesday after the company announced that its PALISADE-3 Phase 3 trial for fasedienol in social anxiety disorder did not meet the primary endpoint.The study aimed to assess intranasal fasedienol for acute anxiety relief during public speaking challenges.<h2 class="st-heading-2">Trial Design And Safety</h2>The trial results showed no statistically significant difference between fasedienol and placebo in reducing anxiety, as measured by the Subjective Units of Distress Scale (SUDS). The least squares mean change from baseline was 13.6 ±1.54 for fasedienol versus 14.0 ±1.51 for placebo, a difference of 0.4.PALISADE-3 was a randomized, double-blind, placebo-controlled U.S. multi-center study. Participants received a single intranasal dose of fasedienol and were assessed during a simulated public speaking challenge.&nbsp;<blockquote>“We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsistent with positive outcomes observed in Phase 2 and our PALISADE-2 Phase 3 study.”-Shawn Singh, President and CEO, Vistagen.&nbsp;</blockquote><h2 class="st-heading-2">How Did Stocktwits Users React?&nbsp;</h2>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/VTGN">Vistagen stock</a> remained in ‘bullish’ territory, and message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:935/115;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_17_103119_png_73b7712123.webp" alt="VTGNs Sentiment Meter and Message Volume as of 10:00 a.m. ET on Dec. 17, 2025 | Source: Stocktwits" width="935" height="115"><figcaption>VTGNs Sentiment Meter and Message Volume as of 10:00 a.m. ET on Dec. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said the drop in the stock may be exaggerated, considering the company has cash, other pipeline projects, and the treatment isn’t completely worthless.<stembedurl>https://stocktwits.com/TheTinyDevil/message/639428997</stembedurl>Another user suggested waiting for PALISADE-4 results.<stembedurl>https://stocktwits.com/bruegis283904/message/639417313</stembedurl>The company said it continues to investigate pherines as a potential new class of intranasal therapeutics targeting neurocircuitry.&nbsp;Lucid Capital downgraded Vistagen stock to ‘Neutral’ from ‘Buy’, and slashed its price target from $19 to $1, citing the Phase 3 PALISADE-3 trial failure and uncertainty about the success of the ongoing PALISADE-4.VTGN stock has declined by over 73% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/warner-bros-discovery-rejects-paramount-bid-and-stands-firm-on-netflix-deal/cLeOilMREqc">Warner Bros. Discovery Rejects Paramount Bid And Stands Firm On Netflix Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration VistaGen Therapeutics, August 8, 2023, Suqian, Jiangsu Province, China. 

Why Did Vistagen Stock Tank 82% Today?

VTGN Stock - The company’s PALISADE-3 Phase 3 trial showed no statistically significant difference between fasedienol and placebo in reducing anxiety.

Equity

The company’s PALISADE-3 Phase 3 trial showed no statistically significant difference between fasedienol and placebo in reducing anxiety.


Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Vistagen Therapeutics Inc.

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$0.6452
Prev Close	$0.6638
Open	$0.65
Dividend Yield	0.00%
50-Day Moving Average	$2.71
Beta	2.03
Avg. Volume	5.71M
PE Ratio	-0.41

52-Week High	$5.14
52-Week Low	$0.6311
Market Capitalization	$26.31M
EPS (Annual)	-$1.67
Price to Book	0.38
Revenue Per Employee	$8,526.32
Enterprise Value/EBITDA	N/A

VTGN
VistaGen Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VTGN News

VTGNVistaGen Therapeutics Inc